Time to viral load suppression in antiretroviral‐naive and ‐experienced HIV‐infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation
Authors:
- 7 August 2013
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 120 (12) , 1534-1547
Abstract
ObjectiveTo compare time to achieve viral load<400copies/ml and <1000copies/ml in HIV-infected antiretroviral (ARV) -naive versus ARV-experienced pregnant women on highly active antiretroviral therapy (HAART). DesignRetrospective cohort study. SettingThree university medical centers, USA. PopulationHIV-infected pregnant women initiated or restarted on HAART during pregnancy. MethodsWe calculated time to viral load<400copies/ml and <1000copies/ml in HIV-infected pregnant women on HAART who reported at least 50% adherence, stratifying based on previous ARV exposure history. Main outcome measuresTime to HIV viral load<400copies/ml and <1000copies/ml. ResultsWe evaluated 138 HIV-infected pregnant women, comprising 76 ARV-naive and 62 ARV-experienced. Ninety-three percent of ARV-naive women achieved a viral load<400copies/ml during pregnancy compared with 92% of ARV-experienced women (P=0.82). The median number of days to achieve a viral load<400copies/ml in the ARV-naive cohort was 25.0 (range 3.5-133; interquartile range 16-34) days compared with 27.0 (range 8-162.5; interquartile range 18.5-54.3) days in the ARV-experienced cohort (P=0.02). In a multiple predictor analysis, women with higher adherence (adjusted relative hazard [aRH] per 10% increase in adherence 1.29, 95% confidence interval [CI] 1.08-1.54, P=0.01) and receiving a non-nucleotide reverse transcriptase inhibitor (NNRTI) -based regimen (aRH 2.48, 95% CI 1.33-4.63, P=0.01) were more likely to achieve viral load<400copies/ml earlier. Increased baseline HIV log(10) viral load was associated with a later time of achieving viral load<400copies/ml (aRH 0.60, 95% CI 0.39-0.92, P=0.02). In a corresponding model of time to achieve viral load<1000copies/ml, adherence (aRH per 10% increase in adherence 1.79, 95% CI 1.34-2.39, P<0.001), receipt of NNRTI (aRH 2.95, 95% CI 1.23-7.06, P=0.02), and CD4 cell count (aRH per 50 count increase in CD4 1.12, 95% CI 1.03-1.22, P=0.01) were associated with an earlier time to achieve viral load below this threshold. Increasing baseline HIV log(10) viral load was associated with a longer time of achieving viral load<1000copies/ml (aRH 0.54, 95% CI 0.34-0.86, P=0.01). In multiple predictor models, previous ARV exposure was not significantly associated with time to achieve viral load below thresholds of <400copies/ml and <1000 copies/ml. ConclusionsPregnant women with 50% adherence, whether ARV-naive or ARV-experienced, on average achieve a viral load<400copies/ml within a median of 26days and a viral load of<1000copies/ml within a median of 14days of HAART initiation. Increased adherence, receipt of NNRTI-based regimen and lower baseline HIV log(10) viral load were all statistically significant predictors of earlier time to achieve viral load<400copies/ml and <1000copies/ml. Increased CD4 count was statistically significant as a predictor of earlier time to achieve viral load<1000copies/ml.Keywords
Funding Information
- UCSF-CTSI (UL1 TR000004)
This publication has 24 references indexed in Scilit:
- Antiretroviral Therapies in Women after Single-Dose Nevirapine ExposureNew England Journal of Medicine, 2010
- Effects of Highly Active Antiretroviral Therapy Duration and Regimen on Risk for Mother-to-Child Transmission of HIV in Johannesburg, South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- The Cost-Effectiveness of Directly Observed Highly-Active Antiretroviral Therapy in the Third Trimester in HIV-Infected Pregnant WomenPLOS ONE, 2010
- Kinetics and Determining Factors of the Virologic Response to Antiretrovirals during PregnancyInfectious Diseases in Obstetrics and Gynecology, 2009
- Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal CohortAIDS, 2008
- Cesarean delivery for HIV-infected women: recommendations and controversiesAmerican Journal of Obstetrics and Gynecology, 2007
- Time to Undetectable Viral Load after Highly Active Antiretroviral Therapy Initiation among HIV-Infected Pregnant WomenClinical Infectious Diseases, 2007
- Characterization of Viral Dynamics in Human Immunodeficiency Virus Type 1–Infected Patients Treated with Combination Antiretroviral Therapy: Relationships to Host Factors, Cellular Restoration, and Virologic End PointsThe Journal of Infectious Diseases, 1999
- Decay characteristics of HIV-1-infected compartments during combination therapyNature, 1997
- Viral dynamics in human immunodeficiency virus type 1 infectionNature, 1995